echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > 2018-2020 Domestic 1 new drug market map

    2018-2020 Domestic 1 new drug market map

    • Last Update: 2021-03-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cuisine 2018 to 2020 these three years, domestic 1 new class of drugs listed into the harvest period, a total of 32 listed (domestic 1 class of new drugs refers to the registration classified as chemical drugs 1, therapeutic biological products 1 drugs, preventive biological products and Chinese medicine is not within the scope of the author's statistics).
    2018 listed domestic category 1 new drugs (Source: NMPA) 2019 listed domestic category 1 new drugs (source: NMPA) 2020 listed domestic category 1 new drugs (source: NMPA) from the year, 2018 and 2019 have 9 new class 1 drugs approved, 2020 outbreak, 14 listed.
    from the point of view of research and development companies, in 2018-2020, Hengrui received the largest number of new drugs in category 1, there are four, namely Malay acid pyrithione, carelli pearl monoanti, fluorine palladium and toluazoleon.
    , three were approved, polyglycol locenaptide, fluoromatininib and amedinib.
    , Goli Pharmaceuticals and Huang were approved, with only one for the rest.
    , Hengrui is still a leading domestic innovation drug enterprises.
    from the approved adaptation, nearly half of the 32 new Class 1 drugs are anti-tumor drugs, followed by anti-infective drugs and narcotic drugs.
    can be seen that cancer drugs are still the most important research and development of domestic class 1 new drugs.
    From the target point of view, the approved 32 new class 1 drugs, PD-1 target the most, a total of 4 PD-1 drugs approved in these three years, followed by PARP, BTK, NS5A each 2, which shows that domestic innovative drugs are more and more up-to-date, research and development targets more and more in line with international standards, and even synchronization.
    the value of a single drug ultimately needs to be judged by the market, and of the 32 domestically available class 1 new drugs, the best selling are the PD-1 drug and the positive atrotinie.
    , Andrrotini is already a Big Mac drug with annual sales of about $3 billion.
    And Hengrui's PD-1 drug Karelliju monoanti-anti-annual sales have exceeded 1 billion yuan, Junshi and Xinda's PD-1 drug Ripley and Syndicate monoanti are also more than 500 million yuan.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.